used API-2 (triciribidine, an AKT inhibitor) and RAD-001 (everolimus, a mTOR inhibitor) to target the PI3K/AKT/mTOR pathway and discovered that the inhibition of cell viability and proliferation in B7-H3 knockdown tumor cells was enhanced relative to that in their counterparts (54) (Figure 3). The gene discussed is AKT1; the disease is neoplasm.